ATRA
Atara Biotherapeutics Inc
8.90$
+4.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +206.2% | -18.8% | -17.5% | +79.9% | -12.5% | +71.5% | -20.4% | -19.6% | -56.0% | -34.1% | -81.5% | |
| – | +206.1% | -19.7% | -33.9% | +86.7% | -15.1% | +91.7% | -26.5% | -23.3% | -65.5% | -36.3% | -81.2% | |
| – | +8.4% | +102.0% | +65.2% | -23.4% | +22.4% | +169.7% | -47.1% | -12.4% | -72.2% | -3.1% | -66.1% | |
| – | +207.8% | -20.2% | -35.0% | +86.4% | -16.3% | +93.2% | -25.9% | -34.6% | -78.7% | -17.8% | -80.0% | |
| – | – | – | – | – | – | – | -21.1% | +3,979.2% | -15.2% | -95.7% | -15.5% | |
| – | – | – | – | – | – | – | – | +158,599,900.0% | +512.0% | +9.8% | -100.0% | |
| – | +462.5% | +1,107.0% | +1,254.1% | +55.4% | -21.0% | -6.8% | +58.2% | -92.1% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +235.9% | +3.1% | +292.2% | +32.7% | -1.5% | +141.1% | +49.9% | +32.5% | +6.0% | -22.0% | -71.5% | |
| – | +256.4% | -0.4% | +185.7% | +44.6% | -8.1% | +125.6% | +27.6% | -25.4% | +80.2% | -5.4% | -88.9% | |
| – | – | – | – | +17.4% | +169.3% | +25.6% | +38.7% | +395.5% | -10.7% | +14.3% | -22.6% | |
| – | +228.4% | +92.2% | +429.6% | -74.7% | +114.1% | -10.6% | +144.0% | -60.4% | -46.4% | +18.5% | -97.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +205.4% | -19.5% | -29.9% | +90.5% | -14.2% | +59.0% | -39.5% | -54.7% | -178.4% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +413.1% | +12.3% | +3.9% | +46.7% | +17.1% | +44.2% | +26.6% | +8.9% | +3.8% | +76.8% | +69.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.